Analysts Set Kenvue Inc. (NYSE:KVUE) Price Target at $25.33

Kenvue Inc. (NYSE:KVUE - Get Free Report) has been assigned a consensus rating of "Hold" from the twelve brokerages that are covering the stock, MarketBeat.com reports. Seven analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $25.33.

KVUE has been the topic of a number of recent analyst reports. UBS Group raised their price target on Kenvue from $24.00 to $25.00 and gave the company a "neutral" rating in a report on Friday, May 9th. Piper Sandler lifted their price objective on shares of Kenvue from $24.00 to $27.00 and gave the company an "overweight" rating in a research report on Monday, February 24th. Evercore ISI began coverage on shares of Kenvue in a research note on Monday, March 24th. They set an "in-line" rating and a $25.00 target price for the company. Canaccord Genuity Group lifted their price target on shares of Kenvue from $24.00 to $29.00 and gave the company a "buy" rating in a report on Wednesday, March 5th. Finally, Citigroup reissued a "neutral" rating on shares of Kenvue in a report on Friday, June 13th.

Kenvue Stock Performance

Shares of NYSE:KVUE traded down $0.10 during midday trading on Wednesday, hitting $21.35. The company had a trading volume of 14,259,316 shares, compared to its average volume of 16,471,614. The company has a market cap of $40.95 billion, a price-to-earnings ratio of 38.81, a PEG ratio of 3.36 and a beta of 0.98. The company has a debt-to-equity ratio of 0.63, a current ratio of 0.86 and a quick ratio of 0.60. The company has a fifty day moving average of $23.02 and a two-hundred day moving average of $22.46. Kenvue has a 12-month low of $17.67 and a 12-month high of $25.17.

Kenvue (NYSE:KVUE - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.24 earnings per share for the quarter, beating analysts' consensus estimates of $0.23 by $0.01. Kenvue had a return on equity of 20.87% and a net margin of 6.90%. The firm had revenue of $3.74 billion for the quarter, compared to analysts' expectations of $3.69 billion. During the same period in the previous year, the firm earned $0.28 EPS. The business's quarterly revenue was down 3.9% on a year-over-year basis. On average, equities research analysts expect that Kenvue will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th were paid a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a yield of 3.84%. The ex-dividend date of this dividend was Wednesday, May 14th. Kenvue's dividend payout ratio (DPR) is presently 149.09%.

Institutional Trading of Kenvue

Hedge funds have recently bought and sold shares of the stock. Pittenger & Anderson Inc. purchased a new position in shares of Kenvue in the 1st quarter worth approximately $30,000. SRS Capital Advisors Inc. boosted its stake in Kenvue by 67.4% in the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock worth $30,000 after purchasing an additional 571 shares in the last quarter. TruNorth Capital Management LLC purchased a new stake in Kenvue during the 1st quarter worth approximately $36,000. Truvestments Capital LLC purchased a new position in shares of Kenvue in the first quarter worth $37,000. Finally, Clal Insurance Enterprises Holdings Ltd lifted its stake in shares of Kenvue by 378.5% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company's stock worth $39,000 after buying an additional 1,287 shares during the period. Hedge funds and other institutional investors own 97.64% of the company's stock.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.